These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 20043026)

  • 1. Pazopanib.
    Bukowski RM; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2010 Jan; 9(1):17-8. PubMed ID: 20043026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pazopanib: therapeutic developments.
    Limvorasak S; Posadas EM
    Expert Opin Pharmacother; 2009 Dec; 10(18):3091-102. PubMed ID: 19954277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pazopanib for the treatment of renal cancer.
    Al-Marrawi MY; Rini B
    Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pazopanib for the treatment of metastatic renal cell carcinoma.
    Pick AM; Nystrom KK
    Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus and pazopanib: two new drugs for renal cell cancer.
    Med Lett Drugs Ther; 2010 May; 52(1337):33-4. PubMed ID: 20431519
    [No Abstract]   [Full Text] [Related]  

  • 6. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma.
    Keisner SV; Shah SR
    Drugs; 2011 Mar; 71(4):443-54. PubMed ID: 21395357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.
    Zivi A; Cerbone L; Recine F; Sternberg CN
    Expert Opin Drug Saf; 2012 Sep; 11(5):851-9. PubMed ID: 22861374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pazopanib: a review of its use in the management of advanced renal cell carcinoma.
    McCormack PL
    Drugs; 2014 Jul; 74(10):1111-25. PubMed ID: 24935162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma.
    Bukowski RM
    Expert Rev Anticancer Ther; 2010 May; 10(5):635-45. PubMed ID: 20469994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pazopanib in renal cell carcinoma.
    Sternberg CN
    Clin Adv Hematol Oncol; 2010 Apr; 8(4):232-3. PubMed ID: 20505644
    [No Abstract]   [Full Text] [Related]  

  • 11. Good tolerability, long-term survival and easy management of side effects in a patient with metastatic renal cell carcinoma treated with pazopanib.
    Frascaroli M; Di Cesare P
    Tumori; 2014; 100(6):e301-4. PubMed ID: 25688516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma.
    Sonpavde G; Hutson TE; Sternberg CN
    Expert Opin Investig Drugs; 2008 Feb; 17(2):253-61. PubMed ID: 18230058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pazopanib outscores sunitinib on tolerability.
    Cancer Discov; 2014 Jan; 4(1):OF8. PubMed ID: 24402960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pazopanib in renal cell carcinoma.
    Ward JE; Stadler WM
    Clin Cancer Res; 2010 Dec; 16(24):5923-7. PubMed ID: 21059813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged survival of a patient with papillary renal cell carcinoma and brain metastases using pazopanib.
    Jacobs C; Kim DW; Straka C; Timmerman RD; Brugarolas J
    J Clin Oncol; 2013 Mar; 31(7):e114-7. PubMed ID: 23319695
    [No Abstract]   [Full Text] [Related]  

  • 16. Pazopanib-induced chylothorax in a patient with renal cell carcinoma.
    Koylu B; Tekin F; Aktas BY; Kilickap S; Koksal D
    Anticancer Drugs; 2022 Jan; 33(1):e555-e557. PubMed ID: 34387587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pazopanib: a promising new agent in the treatment of soft tissue sarcomas.
    Kasper B; Hohenberger P
    Future Oncol; 2011 Dec; 7(12):1373-83. PubMed ID: 22112314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac metastasis from renal cell carcinoma successfully treated with pazopanib: impact of TKIs' antiangiogenic activity.
    Schinzari G; Monterisi S; Signorelli D; Cona MS; Cassano A; Danza F; Barone C
    Tumori; 2014; 100(6):e298-300. PubMed ID: 25688515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nursing considerations for patients receiving pazopanib for renal cell carcinoma.
    Becze E
    ONS Connect; 2012 Feb; 27(2):16-7. PubMed ID: 22375508
    [No Abstract]   [Full Text] [Related]  

  • 20. Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
    Leung HW; Chan AL
    Clin Ther; 2011 Jun; 33(6):708-16. PubMed ID: 21704235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.